Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes

Diabetic nephropathy (DN) is now the single commonest cause of end-stage renal disease (ESRD) worldwide and one of the main causes of death in diabetic patients. It is also acknowledged as an independent risk factor for cardiovascular disease (CVD). Since sitagliptin was approved, many studies have...

ver descrição completa

Detalhes bibliográficos
Autor principal: Mega, Cristina (author)
Outros Autores: Lemos, Edite Teixeira de (author), Fernandes, Rosa (author), Reis, Flávio (author)
Formato: article
Idioma:eng
Publicado em: 2017
Assuntos:
Research in Type 2 diabetes mellitus (T2DM)
Renoprotection
DPP-4 inhibitors
Sitagliptin
ZDF rat
Diabetic nephropathy therapeutic
Texto completo:http://hdl.handle.net/10400.19/4704
País:Portugal
Oai:oai:repositorio.ipv.pt:10400.19/4704

Texto Completo

http://hdl.handle.net/10400.19/4704

Registros relacionados